Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914509 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
A Phase 3 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 3
- Development phase
- 565
- Enrollment target
NCT02914509 is a Phase 3 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 565 participants.
The verdict
NCT02914509, a Phase 3 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 565 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
Interventions
- OTHER Placebo Vehicle
- DRUG Travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2016-11-07 |
| Est. Completion | 2019-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914509
The ClinicalTrials.gov registry entry for NCT02914509 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Vehicle is the first listed.
NCT02914509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02914509 about?
NCT02914509 is a clinical study titled "Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT". The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle glaucoma or ocular hypertension
What is the current status of trial NCT02914509?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 565 participants. The study started on 2016-11-07. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT02914509?
The interventions under investigation include: Placebo Vehicle (OTHER), Travoprost (DRUG).
Who is sponsoring clinical trial NCT02914509?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.